Loss-of-function mutations in BMPR2 have been implicated in the development of primary pulmonary hypertension [76], while the loss of BMPR2 expression appears to be a frequent event in cancer progression, as has been observed, particularly in metastatic variants, in renal cell carcinoma, prostate cancer and bladder cancer [72,73,74,77]. This evidence concerns the gene BMPR2 and prostate carcinoma.